The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. (Q38580783)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Stephen N Davis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

English

0 references

publication date

4 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

2331-2341

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

The emerging global epidemic of type 1 diabetes

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Experiences of using blood glucose targets when following an intensive insulin regimen: a qualitative longitudinal investigation involving patients with Type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Insulin resistance in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Acarbose in the treatment of type I diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Effects of acarbose (Glucobay) in persons with type 1 diabetes: a multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Beta cell mass in diabetes: a realistic therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

GLP-1 agonists in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

The role of adjunctive exenatide therapy in pediatric type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Liraglutide as additional treatment for type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

The role of insulin resistance in the natural history of type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

The use of metformin in type 1 diabetes: a systematic review of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

The effect of rosiglitazone on overweight subjects with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

A review of the efficacy and safety of oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1084502

10.1517/14656566.2015.1084502

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26340427%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference